Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 581-583

  Attivissimo, Lori A ^b   Fetten, James V ^a   Kreis, Willi ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

Chemohormonal therapy; Estramustine; Prostate cancer; Vinblastine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE; VINBLASTINE SULFATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PARESTHESIA; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE; VINBLASTINE;

EID: 0029852763     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00010     Document Type: Article

References (23)

1. Hanks GE, Myers CE, Scardino PT. Cancer of the prostate. In: DeVita VT, Helman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: Lippincott, 1993:1073-113.
2. Catalone WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
3. Group TLS. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-6.
4. Andriole GL. Serum prostate specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer. J Clin Oncol 1993;1:596-7.
5. Kelly K, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 1993;11:607-15.
6. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
7. Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993;7:17-27.
8. Naik HR, Pienta KJ. Current treatment of hormone refractory prostate cancer. Contemp Oncol 1994:51-60.
9. Eisenberger MA, Abrams JS. Chemotherapy for prostatic carcinoma. Semin Urol 1988;6:303-10.
10. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3: 827-41.
11. Eisenberger MA, Bezerdijian L, Kalash S. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol Clin North Am 1987;14:695-706.
12. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine. Two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol 1992;10: 1754-61.
13. Seidman AD, Scher HI, Petrylak D, Dershaw D, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992;147:931-4.
14. Amato RJ, Logothetis CJ, Dexus FH, Sella A, Kilbourn RG, Fitz K. Preliminary results of a Phase II trial of estramustine (Emcyt) and vinblastine (VLB) for patients with progressive hormone refractory prostate cancer. Proc Am Assoc Cancer Res 1991;32:186.
15. Kreis W. Estramustine revisited. In: Muggia FM, ed. Concepts, mechanisms, and new targets for chemotherapy. Boston: Kluwer Academic Publishers, 1995:163-84.
16. Benson R, Hartley-Asp B. Mechanism of action and clinical uses of estramustine. Cancer Invest 1990;8:375-80.
17. Tew KD, Hartly-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology 1984;23:28.
18. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12:2005- 12.
19. Dahlof B, Billstrom A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tublin. Cancer Res 1993;53:4573-81.
20. Speicher LA, Barone LR, Chapman AE, et al. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 1994;86:688-94.
21. Pommerenke EW, Osswald H, Hahn EW, Volm M. Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells. Cancer Lett 1990;55:17-23.
22. Begg CB. Methodological issues in studies of the treatment, diagnosis and etiology of prostate cancer. Semin Oncol 1994;21: 569-79.
23. Fossa SD, Aass N, Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol 1994;21:657-61.